Analyst downgrades 7-18-07: ACA, INTC, NVS and TOT
Posted Jul 18th 2007 11:13AM by Kevin Shult
Filed under: Before the Bell, Analyst Reports, Analyst Upgrades and Downgrades, Bad News, Intel (INTC), Novartis AG ADS (NVS)
MOST NOTEWORTHY: Novartis AG (NVS), Intel (INTC), Total S.A. (TOT), Syniverse Holdings, Inc (SVR) and Kindred Healthcare (KND) were today's noteworthy downgrades:
- Merrill cut Novartis (NYSE: NVS) to Neutral from Buy based on a lack of near-term catalysts. Credit Suisse downgraded shares of the company to Underperform from Neutral on expectations of slowing sales growth in 2H07.
- JMP Securities downgraded Intel (NASDAQ: INTC) to Market Perform from Outperform based on valuation and lower estimates.
- JP Morgan cut Total S.A. (NYSE: TOT) to Neutral from Overweight on valuation.
- Syniverse (NYSE: SVR) was cut to Strong Sell from Sell at Matrix USA as competition in North America is creating a cut in Network Services and Number Portability Services revenue.
- Kindred Healthcare (NYSE: KND) was cut to Underperform from Market Perform at Wachovia based on valuation...
OTHER DOWNGRADES:
- DaVita (NYSE: DVA) was downgraded to Hold from Buy at Deutsche Bank.
Analyst summaries provided by TheFlyOnTheWall.com (subscription required). Tags: aca, aci, analyst, arch coal, ArchCoal, btu, davita, downgrade, dva, fcl, foundation, intc, intel, kindred, knd, novartis, nvs, peabody, rating, svr, syniverse, theflyonthewall.com, tot, total
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
Reader Comments (Page 1 of 1)
8-10-2007 @ 10:33AM
michael hammond said...
Novartis has put together a brilliant marketing campaign to increase sales. The idea; to get kids on Ritalin through school psychologists and psychiatrists was pure genius. They came up with disorders; attention-deficit-disorder, mood-disorder, obsessive compulsive-disorder, anxiety-disorder, conversion-disorder, panic-disorder, phobic-disorder and on and on. All you have to do is hyphen disorder onto an emotion or a disability, whip up a drug to handle it and presto, the money pours in.
And now the other drug companies are copying Novartis.
The best thing is that these new clients as they get older will need more and more Ritalin, as it is basically an amphetamine and most will be on some form of it for the rest of their lives; thus insuring growth. And now I see that they are working on getting babies on it. Wow! Will the brilliance ever cease?
The outrageous allegations that Ritalin is a starter drug that creates addicts that then do street crime are just spurious charges done by people who are jealous of the money that Novartis and their investors make.